Coma probably induced by lorazepam–valproate interaction  by Lee, Sang-Ahm et al.
doi:10.1053/seiz.2002.0590, available online at http://www.idealibrary.com on
Seizure 2002; 11: 124–125
CASE REPORT
Coma probably induced by lorazepam–valproate
interaction
SANG-AHM LEE† , JUNG KYO LEE† & KYOUNG HEO‡
†Department of Neurology and Neurosurgery, Asan Medical Center, University of Ulsan College of
Medicine, Seoul, Korea; ‡Department of Neurology, Yonsei University College of Medicine, Seoul,
Korea
Correspondence to: Sang-Ahm Lee, M.D. Department of Neurology, Asan Medical Center, 388-1, Pungnap-dong,
Songpa-gu, Seoul, 138-736, Korea. E-mail: salee@www.amc.seoul.kr
Both valproate (VPA) and lorazepam (LZP) are primarily cleared from the body by glucuronidation. Concomitant administration
of VPA has been reported to reduce the elimination of LZP. However, it remains unknown whether this drug interaction
is clinically significant. We report a patient with epilepsy who showed that VPA–LZP interaction could result in severe
encephalopathy such as coma.
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INTRODUCTION
Valproate (VPA) encephalopathy is rare but has been
reported1. It is usually associated with hyperam-
monemia. Recently, it was reported that VPA reduces
plasma clearance and increases plasma concentrations
of lorazepam (LZP)2, 3. However, it remains unclear
whether this drug interaction can cause clinically
significant drug toxicity such as coma. We report a
patient with epilepsy who developed coma probably
due to LZP–VPA interaction.
CASE REPORT
A 36-year-old woman with medically intractable
seizures was referred to our center for epilepsy
surgery. Her seizures developed at the age of 27 years.
The risk factors for seizure were absent. General and
neurologic examinations were normal. A brain MRI
demonstrated a left hippocampal atrophy. Prolonged
video-EEG monitoring revealed left temporal inter-
ictal spikes and ictal EEG seizure onset in the left
temporal lobe. Her seizure semiology was compatible
with temporal lobe seizures. She underwent a standard
anterior temporal lobectomy on the 6th March
2000. The pathology report confirmed hippocampal
sclerosis.
She had a normal postoperative recovery and
complained of headaches. VPA (1000 mg/day), PHT
(300 mg/day), and CBZ (400 mg/day) were re-
administered postoperatively. On the 8th March at
11:00 PM, the first complex partial seizure (CPS)
developed after surgery. Intravenous LZP (2 mg)
was administered at that time. On the 9th March,
several CPS recurred. Intravenous LZP (2 mg) was
injected at 6:00 PM and 9:30 PM. The patient was
awake but slightly drowsy during the intervening
periods between seizures. After the last injection at
9:30 PM, she became unconscious and unresponsive.
On the 10th March, the patient’s mental status was
deep stupor to semi-coma. Deep tendon reflexes were
hyperactive in all extremities and Babinski’s sign was
present bilaterally without focal neurological deficits.
Brain CT and MRI scans provided no evidence for
an acute structural lesion. EEG monitoring for 1 day
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revealed generalized theta to delta slowing without
epileptiform discharges. She was transferred to the
intensive care unit. Blood cell count, serum chemistry,
electrolyte and urinalysis were normal. The serum
levels for VPA, PHT, and CBZ were 58.9, 18.1,
and 3.0 mg L−1, respectively. The serum levels for
ammonia were between 31 and 75 µmol L−1. On
the 11th March, she remained in semi-coma and was
intubated. At that time VPA was discontinued. Over
the next 2 days she gradually improved and displayed
a normal mental status with no focal neurological
deficits. She was discharged taking PHT 300 mg/day,
CBZ 400 mg/day, and clobazam 30 mg/day. She has
remained seizure-free for 12 months after discharge.
DISCUSSION
Our patient, who was taking VPA, developed coma
after the injection of a total of 6 mg LZP during
a period of 24 hours. She remained in a coma
for between 48 and 72 hours. At that time we
did not find any possible causes of inducing coma.
EEG monitoring for 1 day did not show evidence
of non-convulsive status epilepticus. The possibility
of acute structural or metabolic abnormalities was
excluded by the imaging and routine blood test. The
normal serum ammonia level excluded VPA-induced
hyperammonemic encephalopathy. The generalized
slowing on EEG and bilateral Babinski’s sign were
suggestive of diffuse encephalopathy. Based on the
exclusion and prompt recovery after the withdrawal
of VPA, it was most likely that the elevated plasma
concentration of LZP due to LZP–VPA interaction
induced her coma, although this was not documented.
Recent evidence has shown that VPA inhibits the
elimination of drugs metabolized by glucuronide
conjugation4, 5. It is well known that VPA reduces
the elimination of lamotrigine, which is principally
cleared by glucuronidation4. Similar to lamotrigine,
LZP is also cleared from the body primarily by
glucuronidation. Recently, two studies2, 3 confirmed
LZP–VPA drug interaction. However, it remains less
well understood how clinically significant this inter-
action is. Anderson et al.2 reported that intersubject
variability of this drug interaction was wide. Our
case serves to emphasize that co-administration of
LZP with VPA may cause significant drug toxicity,
including coma, and clinicians should pay attention to
the possibility of this drug interaction.
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